Advaxis awarded $210,000 for development of a dual antigen vaccine

Advaxis, Incorporated (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been awarded a $210,000 grant from the US National Institute of Health (NIH) to develop a single bioengineered Lm vaccine to deliver two different antigen-adjuvant proteins.

This technology enables a single vaccine to simultaneously attack two separate and distinct tumor targets with a higher level of potency. Further investigational work is focusing on the use of this dual delivery approach directed against a tumor cell surface marker to kill tumor cells directly plus an anti-angiogenic target that would impair a tumor’s ability to grow by simultaneously reducing its blood supply.

“Advaxis continues to invent new ways to use the very powerful live Listeria vaccine platform to treat disease,” commented Advaxis CEO Thomas A. Moore. “The remarkably broad and effective immune response to Listeria vaccines enables us to work with a wide variety of different antigens in order to maximize their efficacy; and now we can work with more than one antigen at a time.”